ALK-Abelló A/S

(PINK:AKBLF)

Latest On ALK-Abelló A/S (AKBLF):

Date/Time Type Description Signal Details
2022-11-10 10:28 ESTNewsALK-Abelló A/S GAAP EPS of DKK 0.23, revenue of DKK 1.06BN/A
2022-08-11 20:41 ESTNewsALK-Abelló A/S reports Q2 resultsN/A
2022-05-12 09:43 ESTNewsALK-Abelló A/S GAAP EPS of $0.70, revenue of $1.16B; reaffirms FY22 guidanceN/A
2022-02-08 10:46 ESTNewsALK-Abelló A/S reports Q4 resultsN/A
2021-05-05 08:46 ESTNewsALK-Abelló A/S reports Q1 resultsN/A
2021-03-18 14:53 ESTEarnings EstimateAn EPS average of -$0.10 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-18 14:53 ESTEarnings EstimateAn EPS average of $1.14 is estimated for the quarter ending on March 31, 2021.Buy
2021-03-18 14:53 ESTEarnings EstimateAn EPS average of $6.13 is estimated for the 2022 year.Buy
2021-02-12 05:43 ESTFinancialsCompany financials have been released.Neutral
2020-12-04 18:21 ESTFinancialsCompany financials have been released.Neutral
2020-11-26 23:41 ESTFinancialsCompany financials have been released.Neutral
2020-11-14 06:57 ESTFinancialsCompany financials have been released.Neutral
2020-11-11 07:55 ESTNewsALK-Abelló A/S reports Q3 resultsN/A
2020-11-08 02:37 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 18:58 ESTFinancialsCompany financials have been released.Neutral
2020-09-26 15:49 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 08:17 ESTFinancialsCompany financials have been released.Neutral
2020-08-15 02:49 ESTFinancialsCompany financials have been released.Neutral
2020-08-14 11:52 ESTFinancialsCompany financials have been released.Neutral
2020-08-06 15:30 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 19:40 ESTFinancialsCompany financials have been released.Neutral
2020-07-30 07:39 ESTFinancialsCompany financials have been released.Neutral
2020-07-29 23:53 ESTFinancialsCompany financials have been released.Neutral
2020-07-28 17:07 ESTFinancialsCompany financials have been released.Neutral
2020-07-27 15:29 ESTFinancialsCompany financials have been released.Neutral
2020-07-23 20:20 ESTFinancialsCompany financials have been released.Neutral
2020-07-09 11:42 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 19:22 ESTFinancialsCompany financials have been released.Neutral
2020-07-01 03:13 ESTFinancialsCompany financials have been released.Neutral
2020-06-19 15:15 ESTFinancialsCompany financials have been released.Neutral
2020-06-14 07:25 ESTFinancialsCompany financials have been released.Neutral
2020-06-12 08:58 ESTFinancialsCompany financials have been released.Neutral
2020-06-02 10:44 ESTEarnings EstimateAn EPS average of -$0.76 is estimated for the quarter ending on September 30, 2020.Sell
2020-05-27 08:03 ESTFinancialsCompany financials have been released.Neutral
2020-05-21 03:43 ESTFinancialsCompany financials have been released.Neutral
2020-05-16 02:55 ESTFinancialsCompany financials have been released.Neutral
2020-05-06 08:21 ESTFinancialsCompany financials have been released.Neutral
2020-05-02 22:54 ESTFinancialsCompany financials have been released.Neutral
2020-05-01 19:12 ESTFinancialsCompany financials have been released.Neutral
2020-04-20 06:59 ESTFinancialsCompany financials have been released.Neutral
2020-04-09 23:08 ESTFinancialsCompany financials have been released.Neutral
2020-04-03 23:36 ESTFinancialsCompany financials have been released.Neutral
2020-03-25 23:04 ESTFinancialsCompany financials have been released.Neutral
2020-02-18 01:56 ESTFinancialsCompany financials have been released.Neutral
2020-02-14 15:55 ESTEarnings EstimateAn EPS average of $2.67 is estimated for the 2021 year.Buy
2020-02-14 15:55 ESTEarnings EstimateAn EPS average of $0.01 is estimated for the 2020 year.Buy
2020-02-14 15:55 ESTEarnings EstimateAn EPS average of $0.09 is estimated for the quarter ending on June 30, 2020.Buy
2020-02-14 15:55 ESTEarnings EstimateAn EPS average of $0.79 is estimated for the quarter ending on March 31, 2020.Buy

About ALK-Abelló A/S (AKBLF):

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including house dust mite, grass, tree, ragweed, and Japanese cedar. Its products include GRAZAX, RAGWITEK, RAGWIZAX, MITICURE, ODACTRA, CEDARCURE, and ITULAZAX for the treatment of allergic rhinitis; and ACARIZAX for treating allergic rhinitis and allergic asthma. ALK-Abelló A/S was founded in 1923 and is headquartered in Hørsholm, Denmark.

See Advanced Chart

General

  • Name ALK-Abelló A/S
  • Symbol AKBLF
  • Type Common Stock
  • Exchange PINK
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 2,447
  • Fiscal Year EndDecember
  • Web URLhttp://www.alk.net
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 7.64
  • Price/Book (Most Recent Quarter) 8.41
  • Enterprise Value Revenue 1.25
  • Enterprise Value EBITDA 11.51
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate $1.61
  • Next Year EPS Estimate $6.13
  • Profit Margin 1%
  • Return on Assets 2%
  • Return on Equity 1%
  • Revenue Per Share $0
  • Gross Profit 2.05 billion
  • Quarterly Earnings Growth 12.2%
View More

Highlights

  • Market Capitalization 4.15 billion
  • PEG Ratio 779.93
View More

Share Statistics

  • Shares Outstanding 9.89 million
  • Shares Float 6.43 million
  • % Held by Insiders <1%
  • % Held by Institutions 61.43%
View More

Technicals

  • Beta 0.19
  • 52 Week High $418
  • 52 Week Low $259.5
  • 50 Day Moving Average 373.2
  • 200 Day Moving Average 287.52
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date 2017-03-16
  • Dividend Yield 0%
View More

ALK-Abelló A/S (AKBLF) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ALK-Abelló A/S (AKBLF) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$N/A-$0.45$0.58-177.59%
2020-09-302020-12-31$N/A-$0.47-$3.3085.62%
2020-06-302020-09-30$N/A-$0.28-$2.3087.68%
2020-03-312020-06-30$956 million-$0.14$3.30-104.11%
2019-12-312020-03-31$132.52 million$1.15-$3.40133.9%
2019-09-302019-12-31$107.89 million-$0.18-$2.6193.15%
2019-06-302019-09-30$118.69 million-$0.19-$2.2891.76%
2019-03-312019-06-30$130.23 million-$0.94$2.40-139.36%
2018-12-312019-03-31$120.87 million$0.62-$2.12129.06%
2018-09-302018-12-31$102.64 million-$20.13-$6.85-193.83%
2018-06-302018-09-30$111.68 million-$0.37-$8.0295.34%
2018-03-312018-06-30$124.19 million-$0.25-$7.3696.59%
2017-12-312018-03-31$123.03 million$0.36-$2.02117.62%
2017-09-302017-12-31$105.14 million-$2.36-$1.47-60.63%
2017-06-302017-08-16$691 million-$0.02$1.90-100.79%
2017-03-312017-06-30-$0.02
2016-12-312017-03-31$0.03$3.30-99.12%
2016-09-302016-12-31$0.51$2.80-81.83%
2016-06-302016-09-30$0.60$4.70-87.16%
2016-03-312016-06-30$1.04$9.55-89.06%
2015-12-312016-03-31$1.83
2015-09-302015-12-31$2.01-$0.73374.73%
2015-06-302015-09-30$0.90-$0.80212.18%
2015-03-312015-06-30$0.75
2014-12-312015-03-31$1.30$5.74-77.35%
2014-09-302014-12-31$0.26-$0.96127.48%
2014-06-302014-09-30$0.45$1.09-59.09%
2014-03-312014-06-30$0.57$6.63-91.33%
2013-12-312014-03-31$2.01$3.21-37.34%
2013-09-302013-12-31$0.75$0.00
2013-06-302013-09-30$0.17$0.00
2013-03-312013-06-30-$0.54$0.00
2012-12-312013-03-31$0.74$0.00
2012-09-302012-12-31-$0.27$0.00
2012-06-302012-09-30$0.99$0.00
2012-03-312012-06-30-$0.47$0.00
2011-12-312012-03-31$0.73$0.00
2011-09-302011-12-31$0.34$0.00
2011-06-302011-09-30$0.75$0.00
2011-03-312011-06-30$0.26$0.00
2010-12-312011-03-31$2.44$0.00
2010-09-302010-12-31$0.72$0.00

ALK-Abelló A/S (AKBLF) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A 113 million 22.36 million
Income Before Tax N/A N/A N/A 122 million -2.1 million
Selling General Administrative N/A N/A N/A 335 million 58.53 million
Gross Profit N/A N/A N/A 585 million 77.29 million
Ebit N/A N/A N/A 198 million -4.5 million
Operating Income N/A N/A N/A 137 million -4.5 million
Income Tax Expense 17 million 7 million 16 million 36 million 2.25 million
Total Revenue N/A N/A N/A 956 million 132.52 million
Cost of Revenue N/A N/A N/A 371 million 55.23 million
Total Other Income Expense Net N/A N/A N/A N/A 2.4 million
Net Income From Continuing Operations N/A N/A N/A 86 million -4.35 million
Net Income Applicable to Common Shares -31 million -20 million -10 million 86 million -4.35 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A -49 million 150082.55 145989.66
Change to Liabilities N/A N/A N/A 23.86 million N/A
Total Cash Flow from Investing Activities -46 million -78 million -49 million -4.95 million -6.13 million
Net Borrowings -16 million -11 million -10 million -2.55 million -1.02 million
Total Cash Flow from Financial Activities N/A N/A N/A -1.35 million -1.02 million
Change to Operating Activities -90 million 56 million -135 million 28.52 million -1.9 million
Change in Cash N/A N/A 7 million 22.36 million -5.84 million
Total Cash from Operating Activities -48 million 84 million 70 million 28.82 million 1.02 million
Depreciation N/A N/A 61 million 3.75 million 7.88 million
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A -8.1 million -7.88 million
Change to Account Receivables N/A N/A N/A -30.02 million -29.2 million
Other Cash Flow from Financing Activities N/A -20 million -4 million N/A N/A
Change to Net Income 182 million -21 million 58 million 10.21 million -2.92 million
Capital Expenditures N/A N/A 49 million 8.1 million 5.26 million
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A 2.36 billion 348.04 million
Total Stockholder Equity N/A N/A N/A 3.28 billion 476.66 million
Other Current Liabilities 905 million 818 million N/A N/A 120.67 million
Total Assets N/A N/A N/A 5.64 billion 824.7 million
Common Stock 111 million 111 million 111 million 111 million 16.66 million
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings 3.17 billion 3.16 billion 3.16 billion 3.17 billion 462.85 million
Other Liabilities 488 million 485 million 476 million 458 million 66.64 million
Other Assets 895 million 851 million 863 million 817 million 117.06 million
Cash N/A N/A N/A 322 million 47.43 million
Total Current Liabilities 1.03 billion 976 million N/A 968 million 140.18 million
Other Stockholder Equity -125 million -72 million -27 million N/A -2.85 million
Property, Plant & Equipment 1.7 billion 1.72 billion 1.74 billion 1.76 billion 260.99 million
Total Current Assets 2.34 billion 2.3 billion N/A 2.35 billion 337.39 million
Long Term Investments N/A N/A N/A N/A 6.9 million
Net Tangible Assets 2.53 billion 2.55 billion 2.58 billion 2.6 billion 374.31 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A 703 million 106.11 million
Inventory 1.09 billion 1.13 billion N/A 1.06 billion 158.49 million
Accounts Payable 74 million 109 million N/A 106 million 12.16 million

ALK-Abelló A/S (AKBLF) Chart:

ALK-Abelló A/S (AKBLF) News:

Below you will find a list of latest news for ALK-Abelló A/S (AKBLF) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ALK-Abelló A/S (AKBLF) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

ALK-Abelló A/S (AKBLF) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link